193 related articles for article (PubMed ID: 12642465)
1. Functional characterization of cytochrome P450 2B6 allelic variants.
Jinno H; Tanaka-Kagawa T; Ohno A; Makino Y; Matsushima E; Hanioka N; Ando M
Drug Metab Dispos; 2003 Apr; 31(4):398-403. PubMed ID: 12642465
[TBL] [Abstract][Full Text] [Related]
2. Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2-CYP2B6.28, except CYP2B6.22).
Watanabe T; Sakuyama K; Sasaki T; Ishii Y; Ishikawa M; Hirasawa N; Hiratsuka M
Pharmacogenet Genomics; 2010 Jul; 20(7):459-62. PubMed ID: 20517174
[TBL] [Abstract][Full Text] [Related]
3. Examination of purported probes of human CYP2B6.
Ekins S; VandenBranden M; Ring BJ; Wrighton SA
Pharmacogenetics; 1997 Jun; 7(3):165-79. PubMed ID: 9241656
[TBL] [Abstract][Full Text] [Related]
4. Functional characterization of CYP2B6 allelic variants in demethylation of antimalarial artemether.
Honda M; Muroi Y; Tamaki Y; Saigusa D; Suzuki N; Tomioka Y; Matsubara Y; Oda A; Hirasawa N; Hiratsuka M
Drug Metab Dispos; 2011 Oct; 39(10):1860-5. PubMed ID: 21746968
[TBL] [Abstract][Full Text] [Related]
5. Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex.
Zhang H; Sridar C; Kenaan C; Amunugama H; Ballou DP; Hollenberg PF
J Pharmacol Exp Ther; 2011 Sep; 338(3):803-9. PubMed ID: 21659470
[TBL] [Abstract][Full Text] [Related]
6. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation.
Code EL; Crespi CL; Penman BW; Gonzalez FJ; Chang TK; Waxman DJ
Drug Metab Dispos; 1997 Aug; 25(8):985-93. PubMed ID: 9280407
[TBL] [Abstract][Full Text] [Related]
7. Determination of CYP2B6 component of 7-ethoxy-4-trifluoromethylcoumarin O-deethylation activity in human liver microsomes.
Chang TK; Crespi CL; Waxman DJ
Methods Mol Biol; 2006; 320():97-102. PubMed ID: 16719378
[TBL] [Abstract][Full Text] [Related]
8. Bioactivation of chlorpyrifos by CYP2B6 variants.
Crane AL; Klein K; Olson JR
Xenobiotica; 2012 Dec; 42(12):1255-62. PubMed ID: 22775490
[TBL] [Abstract][Full Text] [Related]
9. Functional characterization of 40 CYP2B6 allelic variants by assessing efavirenz 8-hydroxylation.
Watanabe T; Saito T; Rico EMG; Hishinuma E; Kumondai M; Maekawa M; Oda A; Saigusa D; Saito S; Yasuda J; Nagasaki M; Minegishi N; Yamamoto M; Yamaguchi H; Mano N; Hirasawa N; Hiratsuka M
Biochem Pharmacol; 2018 Oct; 156():420-430. PubMed ID: 30201214
[TBL] [Abstract][Full Text] [Related]
10. Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
Xu C; Ogburn ET; Guo Y; Desta Z
Drug Metab Dispos; 2012 Apr; 40(4):717-25. PubMed ID: 22232427
[TBL] [Abstract][Full Text] [Related]
11. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.
Desta Z; Saussele T; Ward B; Blievernicht J; Li L; Klein K; Flockhart DA; Zanger UM
Pharmacogenomics; 2007 Jun; 8(6):547-58. PubMed ID: 17559344
[TBL] [Abstract][Full Text] [Related]
12. Functional characterization of single nucleotide polymorphisms with amino acid substitution in CYP1A2, CYP2A6, and CYP2B6 found in the Japanese population.
Iwasaki M; Yoshimura Y; Asahi S; Saito K; Sakai S; Morita S; Takenaka O; Inoda T; Kashiyama E; Aoyama A; Nakabayashi T; Omori S; Kuwabara T; Izumi T; Nakamura K; Takanaka K; Nakayama Y; Takeuchi M; Nakamura H; Kametani S; Terauchi Y; Hashizume T; Nagayama S; Kume T; Achira M; Kawai H; Kawashiro T; Nakamura A; Nakai Y; Kagayama A; Shiraga T; Niwa T; Yoshimura T; Morita J; Ohsawa F; Tani M; Osawa N; Ida K; Noguchi K
Drug Metab Pharmacokinet; 2004 Dec; 19(6):444-52. PubMed ID: 15681899
[TBL] [Abstract][Full Text] [Related]
13. Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo.
Raccor BS; Claessens AJ; Dinh JC; Park JR; Hawkins DS; Thomas SS; Makar KW; McCune JS; Totah RA
Drug Metab Dispos; 2012 Jan; 40(1):54-63. PubMed ID: 21976622
[TBL] [Abstract][Full Text] [Related]
14. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6.
Mo SL; Liu YH; Duan W; Wei MQ; Kanwar JR; Zhou SF
Curr Drug Metab; 2009 Sep; 10(7):730-53. PubMed ID: 19702527
[TBL] [Abstract][Full Text] [Related]
15. Effect of CYP2B6*6 and CYP2C19*2 genotype on chlorpyrifos metabolism.
Crane AL; Klein K; Zanger UM; Olson JR
Toxicology; 2012 Mar; 293(1-3):115-122. PubMed ID: 22281205
[TBL] [Abstract][Full Text] [Related]
16. Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin.
Heyn H; White RB; Stevens JC
Drug Metab Dispos; 1996 Sep; 24(9):948-54. PubMed ID: 8886603
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.
Hesse LM; He P; Krishnaswamy S; Hao Q; Hogan K; von Moltke LL; Greenblatt DJ; Court MH
Pharmacogenetics; 2004 Apr; 14(4):225-38. PubMed ID: 15083067
[TBL] [Abstract][Full Text] [Related]
18. Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
Bae SH; Kwon MJ; Choi EJ; Zheng YF; Yoon KD; Liu KH; Bae SK
Chem Biol Interact; 2013 Sep; 205(1):11-9. PubMed ID: 23777987
[TBL] [Abstract][Full Text] [Related]
19. Metabolism of endosulfan-alpha by human liver microsomes and its utility as a simultaneous in vitro probe for CYP2B6 and CYP3A4.
Casabar RC; Wallace AD; Hodgson E; Rose RL
Drug Metab Dispos; 2006 Oct; 34(10):1779-85. PubMed ID: 16855053
[TBL] [Abstract][Full Text] [Related]
20. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.
Gerber JG; Rhodes RJ; Gal J
Chirality; 2004 Jan; 16(1):36-44. PubMed ID: 14628297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
